A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
Status:
Active, not recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled multicenter study evaluating the safety and
efficacy of Rituximab (Mabthera®) in patients with new onset generalized myasthenia gravis
(MG).